94 related articles for article (PubMed ID: 29346131)
1. Toxicological profile and safety pharmacology of a single dose of fibroblast activation protein-α-based doxorubicin prodrug: in-vitro and in-vivo evaluation.
Huang S; Zhang Y; Zhong J; Pan Y; Cai S; Xu J
Anticancer Drugs; 2018 Mar; 29(3):253-261. PubMed ID: 29346131
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug.
Huang S; Fang R; Xu J; Qiu S; Zhang H; Du J; Cai S
J Drug Target; 2011 Aug; 19(7):487-96. PubMed ID: 21284542
[TBL] [Abstract][Full Text] [Related]
3. A novel FAPα-based Z-Gly-Pro epirubicin prodrug for improving tumor-targeting chemotherapy.
Wang J; Li Q; Li X; Yuan W; Huang S; Cai S; Xu J
Eur J Pharmacol; 2017 Nov; 815():166-172. PubMed ID: 28919026
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeting efficacy of a BF211 prodrug through hydrolysis by fibroblast activation protein-α.
Chai XP; Sun GL; Fang YF; Hu LH; Liu X; Zhang XW
Acta Pharmacol Sin; 2018 Mar; 39(3):415-424. PubMed ID: 29119969
[TBL] [Abstract][Full Text] [Related]
5. Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug: formulation and pharmacokinetic evaluation.
Zhang Y; Zhang X; Liu H; Cai S; Wu B
Int J Nanomedicine; 2015; 10():1625-36. PubMed ID: 25759584
[TBL] [Abstract][Full Text] [Related]
6. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
Kratz F; Ehling G; Kauffmann HM; Unger C
Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
[TBL] [Abstract][Full Text] [Related]
7. A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo.
Tarasenko N; Cutts SM; Phillips DR; Berkovitch-Luria G; Bardugo-Nissim E; Weitman M; Nudelman A; Rephaeli A
Biochem Pharmacol; 2014 Mar; 88(2):158-68. PubMed ID: 24463168
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast Activation Protein α Activated Tripeptide Bufadienolide Antitumor Prodrug with Reduced Cardiotoxicity.
Deng LJ; Wang LH; Peng CK; Li YB; Huang MH; Chen MF; Lei XP; Qi M; Cen Y; Ye WC; Zhang DM; Chen WM
J Med Chem; 2017 Jul; 60(13):5320-5333. PubMed ID: 28595013
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates.
Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM
Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987
[TBL] [Abstract][Full Text] [Related]
10. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy.
Devalapally H; Rajan KS; Akkinepally RR; Devarakonda RK
Drug Dev Ind Pharm; 2008 Aug; 34(8):789-95. PubMed ID: 18608462
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anti-tumor efficiency of gemcitabine prodrug by FAPα-mediated activation.
Sun J; Yang D; Cui SH; Zhang HT; Fu Y; Wang JC; Zhang Q
Int J Pharm; 2019 Mar; 559():48-57. PubMed ID: 30677483
[TBL] [Abstract][Full Text] [Related]
13. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of PolyMPC-Dox Prodrugs in a Human Ovarian Tumor Model.
Wong KE; Mora MC; Skinner M; McRae Page S; Crisi GM; Arenas RB; Schneider SS; Emrick T
Mol Pharm; 2016 May; 13(5):1679-87. PubMed ID: 27023764
[TBL] [Abstract][Full Text] [Related]
15. Amphiphilic polyelectrolyte/prodrug nanoparticles constructed by synergetic electrostatic and hydrophobic interactions with cooperative pH-sensitivity for controlled doxorubicin delivery.
Huang P; Wang W; Zhou J; Zhao F; Zhang Y; Liu J; Liu J; Dong A; Kong D; Zhang J
ACS Appl Mater Interfaces; 2015 Mar; 7(11):6340-50. PubMed ID: 25746122
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Evaluation of a CBZ-AAN-Dox Prodrug and its in vitro Effects on SiHa Cervical Cancer Cells Under Hypoxic Conditions.
Chen H; Liu X; Clayman ES; Shao F; Xiao M; Tian X; Fu W; Zhang C; Ruan B; Zhou P; Liu Z; Wang Y; Rui W
Chem Biol Drug Des; 2015 Oct; 86(4):589-98. PubMed ID: 25619622
[TBL] [Abstract][Full Text] [Related]
17. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
Chen M; Lei X; Shi C; Huang M; Li X; Wu B; Li Z; Han W; Du B; Hu J; Nie Q; Mai W; Ma N; Xu N; Zhang X; Fan C; Hong A; Xia M; Luo L; Ma A; Li H; Yu Q; Chen H; Zhang D; Ye W
J Clin Invest; 2017 Oct; 127(10):3689-3701. PubMed ID: 28846068
[TBL] [Abstract][Full Text] [Related]
18. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy.
Khaliq NU; Sandra FC; Park DY; Lee JY; Oh KS; Kim D; Byun Y; Kim IS; Kwon IC; Kim SY; Yuk SH
Biomaterials; 2016 Sep; 101():131-42. PubMed ID: 27286189
[TBL] [Abstract][Full Text] [Related]
20. A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery.
Du C; Deng D; Shan L; Wan S; Cao J; Tian J; Achilefu S; Gu Y
Biomaterials; 2013 Apr; 34(12):3087-97. PubMed ID: 23374705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
